| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1556-0864(15)30415-9 |
| P698 | PubMed publication ID | 17409969 |
| P2093 | author name string | Chih-Hsin Yang | |
| Claire Watkins | |||
| Alex Chang | |||
| Eng Huat Tan | |||
| Nick Thatcher | |||
| Reury-Perng Perng | |||
| Chao-Jung Tsao | |||
| Sumitra Thongprasert | |||
| Purvish Parikh | |||
| Domingo Ganzon | |||
| Nick Botwood | |||
| P2860 | cites work | EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial | Q29396936 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | Q29615475 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer | Q33218784 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
| Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer | Q35956595 | ||
| Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America | Q36144700 | ||
| Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy | Q36346977 | ||
| Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines | Q36821859 | ||
| Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib | Q44936060 | ||
| Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer | Q44968652 | ||
| Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers | Q46443638 | ||
| Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer | Q46585170 | ||
| Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials | Q46735180 | ||
| Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria | Q47378801 | ||
| What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. | Q53450591 | ||
| Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 | ||
| P433 | issue | 8 | |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 847-855 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study | |
| P478 | volume | 1 |
| Q28541175 | Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer |
| Q36427587 | Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis |
| Q26798228 | Clinical experiences with molecular targeted therapy in lung cancer in China |
| Q36075942 | Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. |
| Q37560695 | Clinical study on gefitinib combined with γ-ray stereotactic body radiation therapy as the first-line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085). |
| Q64963036 | Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification. |
| Q35596686 | Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond |
| Q37634419 | Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma |
| Q43261058 | Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib |
| Q33892582 | Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). |
| Q28284519 | Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC) |
| Q44740671 | Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy |
| Q37060971 | Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples |
| Q37431620 | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer |
| Q38168795 | Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies |
| Q36224756 | Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. |
| Q37595242 | Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. |
| Q36470136 | First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. |
| Q38088215 | First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments |
| Q28385559 | From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience |
| Q36740873 | Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study |
| Q50041281 | Gefitinib for advanced non-small cell lung cancer. |
| Q27023100 | Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review |
| Q38338492 | Gefitinib: a review of its use in adults with advanced non-small cell lung cancer |
| Q37620345 | Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer |
| Q42345482 | Lung cancer in India: Current status and promising strategies |
| Q36772562 | Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer |
| Q33891529 | Network meta-analysis of survival data with fractional polynomials |
| Q37458170 | Next generation oncology drug development: opportunities and challenges |
| Q64094104 | Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients |
| Q37822780 | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations |
| Q36439506 | Positron emission tomography-computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma |
| Q35382420 | Post-trial access to treatment for patients participating in clinical trials |
| Q37458182 | Reasons for response differences seen in the V15-32, INTEREST and IPASS trials |
| Q37274578 | Research status and funding trends of lung cancer biomarkers |
| Q26750428 | Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients |
| Q44521642 | Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases |
| Q54977347 | Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. |
| Q36051729 | Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China |
| Q35628597 | Targeted therapies for non-small cell lung cancer: an evolving landscape |
| Q36214500 | The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis |
| Q92653813 | The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly |
| Q37102068 | The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement |
| Q49218909 | YM155 inhibits topoisomerase function |
| Q88585706 | [Clinical characteristics and risk factors affecting outcomes of elderly patients with non-small cell lung cancer complicated by chronic obstructive pulmonary disease] |
| Q54364040 | [Graphic Evolution Witness the Development of Lung Cancer Translational Research]. |
Search more.